wet age-related macular degeneration
Roche’s Vabysmo Preserves RVO Patients’ Vision with 4-Month Treatment Intervals in Phase III Trials
Anika Sharma
Roche has unveiled promising long-term findings from the global phase III BALATON and COMINO trials, which investigated the extended treatment ...
FDA Approves Eylea HD Injection 8 mg for the Treatment of Wet Age-related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy
Anika Sharma
On August 18, 2023, Regeneron Pharmaceuticals announced a groundbreaking development in the field of ophthalmology: the US Food and Drug ...
Regeneron has faced an unexpected rejection from the FDA for its high-dose version of Eylea due to manufacturing challenges
SG Tylor
Source – Regeneron Regeneron’s highly anticipated high-dose version of Eylea has suffered an unexpected setback as the FDA rejected its ...
